Media coverage about Cutera (NASDAQ:CUTR) has trended somewhat positive on Thursday, Accern reports. The research group scores the sentiment of press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cutera earned a coverage optimism score of 0.09 on Accern’s scale. Accern also assigned news coverage about the medical device company an impact score of 45.6871502599793 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
CUTR has been the topic of several analyst reports. BidaskClub raised shares of Cutera from a “hold” rating to a “buy” rating in a research report on Saturday, August 12th. Gabelli reissued a “buy” rating on shares of Cutera in a research report on Wednesday, August 9th. Maxim Group downgraded shares of Cutera from a “buy” rating to a “hold” rating in a research report on Thursday, September 14th. TheStreet raised shares of Cutera from a “c” rating to a “b” rating in a research report on Friday, August 18th. Finally, Roth Capital lifted their target price on shares of Cutera from $41.00 to $47.00 and gave the stock a “buy” rating in a research report on Tuesday, September 12th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $37.33.
Shares of Cutera (NASDAQ:CUTR) traded down 2.54% on Thursday, reaching $42.25. 64,056 shares of the company were exchanged. The stock has a 50 day moving average price of $39.68 and a 200-day moving average price of $28.06. The stock has a market capitalization of $591.71 million, a P/E ratio of 90.86 and a beta of 0.53. Cutera has a 12 month low of $12.45 and a 12 month high of $44.40.
Cutera (NASDAQ:CUTR) last posted its earnings results on Monday, August 7th. The medical device company reported $0.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.03 by $0.10. Cutera had a return on equity of 11.64% and a net margin of 5.07%. The business had revenue of $36.40 million during the quarter, compared to analysts’ expectations of $32.08 million. During the same period in the prior year, the business earned $0.07 EPS. Cutera’s revenue for the quarter was up 32.4% compared to the same quarter last year. On average, equities analysts expect that Cutera will post $0.52 EPS for the current fiscal year.
Cutera announced that its board has initiated a share repurchase program on Monday, August 7th that allows the company to buyback $25.00 million in shares. This buyback authorization allows the medical device company to repurchase up to 6.8% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s board believes its shares are undervalued.
In related news, CFO Ronald J. Santilli sold 5,775 shares of the stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $40.43, for a total transaction of $233,483.25. Following the completion of the sale, the chief financial officer now directly owns 50,012 shares of the company’s stock, valued at approximately $2,021,985.16. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director David B. Apfelberg sold 1,000 shares of the stock in a transaction that occurred on Monday, September 18th. The stock was sold at an average price of $38.45, for a total value of $38,450.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 56,309 shares of company stock valued at $1,965,520. 11.60% of the stock is owned by company insiders.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Markets Daily and is owned by of Markets Daily. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.themarketsdaily.com/2017/10/12/cutera-cutr-receives-media-impact-rating-of-0-09.html.
Cutera Company Profile
Cutera, Inc is a medical device company. The Company is engaged in the design, development, manufacture, marketing and servicing of laser and other energy-based aesthetics systems for practitioners across the world. The Company offers products based on product platforms, such as enlighten, excel HR, truSculpt, excel V and xeo, each of which enables physicians and other practitioners to perform aesthetic procedures for customers.
Receive News & Ratings for Cutera Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera Inc. and related companies with MarketBeat.com's FREE daily email newsletter.